The packet records one gene, BCL10 (chromosome 1), as associated with this condition. No ClinGen gene-disease validity classification is supplied for BCL10, so the strength of the association is not certified here. One synonym in the packet is 'lymphoma, MALT, somatic', but the packet gives no molecular mechanism, so how BCL10 relates to the condition is not described in this packet. The inheritance field lists MULTIFACTORIAL; the packet supplies no recurrence figures, penetrance or other inheritance details. The definition states that gastric involvement is associated with H. pylori infection; this is an association as stated by the source, and the packet does not describe a causal pathway. The packet does not supply other risk factors.

The packet contains no diagnostic methods, diagnostic criteria or GeneReviews diagnosis content for this condition, so no testing approach is certified here. The phenotype annotations are descriptive frequency data and are not diagnostic criteria. No newborn screening (RUSP) information is recorded. The absence of diagnostic information in this packet reflects what was supplied and does not indicate that no diagnostic approaches exist.

The approved-treatment record in the packet lists one product with an active FDA market status: lenalidomide (REVLIMID), approved through an NDA reviewed by CDER, with an approval date of 2005-12-27. The same product appears in the orphan-drug records with the indication 'treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue'. The packet does not state the full labelled indications of the approval. The orphan-drug records also contain entries labelled DESIGNATED, WITHDRAWN or APPROVED for several other agents, including some entries whose listed indications concern other lymphomas or a non-lymphoma condition. Orphan designation is not FDA approval, and only the lenalidomide record is certified in the approved-treatment field as a current FDA-approved option in this packet. The packet supplies no foundational therapies, no GeneReviews management content and no information on treatment selection, staging or care teams, so none is described here.

Prognosis is not certified in this packet. No natural history or survival information is supplied, and the definition's description of the condition as indolent is the only course-related statement available.

The packet's clinical-trial summary indicates that active ClinicalTrials.gov records exist for the search term MALT lymphoma, with ten detailed records supplied. Examples include NCT07029217, a Phase 3 study of reduced dose radiation therapy for people with B-cell lymphomas (Memorial Sloan Kettering Cancer Center; recruiting; start 2025-06-09, completion 2028-06-01), and NCT05100862, a Phase 3 study comparing zanubrutinib plus anti-CD20 with lenalidomide plus rituximab in relapsed or refractory follicular or marginal zone lymphoma (BeOne Medicines; active, not recruiting; start 2022-03-10, completion 2030-06-01). Other records include Phase 1 and Phase 2 studies and two records without a listed phase. Several listed studies address B-cell malignancies or lymphomas more broadly than this specific condition, and trial titles are not claims about the effect of any intervention. The packet's publication digest classifies 624 items, with case reports and case series as the dominant type, and notes the presence of gene therapy, biomarker and recent trial publications.